SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

CCI dismisses complaint against Cipla, BCDA

21 May 2019 Evaluate

The Competition Commission of India (CCI) has dismissed a complaint against Cipla and the Bengal Chemist and Druggists Association (BCDA) over alleged non-supply of medicines.

While dismissing the complaint, the fair-trade regulator said the complainant tried to give a commercial dispute between him and Cipla a colour of competition issue. The complainant had alleged that despite placement of repeated orders, Cipla had stopped the supply of medicines at the behest of BCDA.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1233.00 -5.30 (-0.43%)
20-Apr-2026 09:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.45
Dr. Reddys Lab 1235.10
Cipla 1233.00
Zydus Lifesciences 939.95
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×